28th Jan 2014 09:37
LONDON (Alliance News) - Avacta Group PLC said Tuesday that that it had launched a new web site to commercialise its Affimer reagents, which are engineered alternatives to antibodies.
The biotechnology company said the new website marks the start of the commercialisation of the Affimers. It said it is also working on developing a catalogue of reagents, substances added to a system to cause a chemical reaction, to be added to the website later in the year.
Shares in Avacta were trading up 3.6% at 1.13 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group